This inventor holds 2 USPTO granted patents. Top assignee: Center for Blood Research, Inc.. Active years: 1994-1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1994-1999
Title: Michael S. Diamond: Innovator in Immunology
Introduction
Michael S. Diamond is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of immunology. With a total of 2 patents to his name, he has made notable advancements in understanding immune responses and the mechanisms of cell activation.
Latest Patents
One of his latest patents focuses on antibodies that bind a subpopulation of Mac-1 (CD11b/CD18) molecules. This invention is based on the novel observation that upon stimulation of resting myeloid cells, not all Mac-1 molecules expressed by the cell become activated. Only select subpopulations of Mac-1 molecules are activated and capable of binding ligands. Furthermore, the activated Mac-1 molecules possess activation-specific epitopes that distinguish them from non-activated Mac-1 molecules. The patent describes antibodies that selectively bind activated Mac-1 molecules while being substantially incapable of binding non-activated Mac-1.
Career Highlights
Michael S. Diamond is affiliated with the Center for Blood Research, Inc., where he continues to explore innovative solutions in the field of immunology. His work has contributed to a deeper understanding of immune cell behavior and the development of targeted therapies.
Collaborations
He has collaborated with notable colleagues, including Timothy Alan Springer and Donald E. Staunton, who share his commitment to advancing research in immunology.
Conclusion
Michael S. Diamond's innovative work in the field of immunology, particularly his patents related to Mac-1 molecules, showcases his dedication to enhancing our understanding of immune responses. His contributions are paving the way for future advancements in targeted therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile